分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling

Ma Ning, Wang Yi-Kang, Xu Sheng, Ni Qian-Zhi, Zheng Qian-Wen, Zhu Bing, Cao Hui-Jun, Jiang Hao, Zhang Feng-Kun, Yuan Yan-Mei, Zhang Er-Bin, Chen Tian-Wei, Xia Ji, Ding Xu-Fen, Chen Zhen-Hua, Zhang Xi

Journal:Nature Communications

IF:14.92

DOI:10.1038/s41467-021-23285-8

PMID:34031390

Published:2021-05-24

research field:

Abstract

Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease in the world, however, no drug treatment has been approved for this disease. Thus, it is urgent to find effective therapeutic targets for clinical intervention. In this study, we find that liver-specific knockout of PPDPF (PPDPF-LKO) leads to spontaneous fatty liver formation in a mouse model at 32 weeks of age on chow diets, which is enhanced by HFD. Mechanistic study reveals that PPDPF negatively regulates mTORC1-S6K-SREBP1 signaling. PPDPF interferes with the interaction between Raptor and CUL4B-DDB1, an E3 ligase complex, which prevents ubiquitination and activation of Raptor. Accordingly, liver-specific PPDPF overexpression effectively inhibits HFD-induced mTOR signaling activation and hepatic steatosis in mice. These results suggest that PPDPF is a regulator of mTORC1 signaling in lipid metabolism, and may be a potential therapeutic candidate for NAFLD.

本文使用的Yeasen产品

购物车
客服
转染试用